The University of Southampton
University of Southampton Institutional Repository

Development and evaluation of psychotropic drugs

Development and evaluation of psychotropic drugs
Development and evaluation of psychotropic drugs
Existing pharmacological treatments for mental disorders are not ideal, and there is much scope for the development of new compounds likely to be associated with improved effectiveness and acceptability in clinical practice. The appearance of a novel psychotropic drug treatment is the result of many years of diligent work from pre-clinical and clinical scientists and considerable scrutiny from regulatory bodies. Most compounds with the potential for clinical use do not enter the comparatively late stage of randomized controlled trials, and some medications are withdrawn from use once safety and tolerability problems are identified in routine clinical samples. This contribution describes the phases of psychotropic drug development, highlights some aspects of study design in the evaluation of potential treatments prior to licensing, and considers likely future challenges in this research environment.
psychotropic drugs, evaluation, anxiety, depression, drug development, placebo, psychopharmacology, randomized controlled trials
279-283
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Ajel, Khalil
4cd2fee4-e3f9-4fb6-b73e-fbfd8b50b40a
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Ajel, Khalil
4cd2fee4-e3f9-4fb6-b73e-fbfd8b50b40a

Baldwin, David S. and Ajel, Khalil (2007) Development and evaluation of psychotropic drugs. Psychiatry, 6 (7), 279-283. (doi:10.1016/j.mppsy.2007.04.002).

Record type: Article

Abstract

Existing pharmacological treatments for mental disorders are not ideal, and there is much scope for the development of new compounds likely to be associated with improved effectiveness and acceptability in clinical practice. The appearance of a novel psychotropic drug treatment is the result of many years of diligent work from pre-clinical and clinical scientists and considerable scrutiny from regulatory bodies. Most compounds with the potential for clinical use do not enter the comparatively late stage of randomized controlled trials, and some medications are withdrawn from use once safety and tolerability problems are identified in routine clinical samples. This contribution describes the phases of psychotropic drug development, highlights some aspects of study design in the evaluation of potential treatments prior to licensing, and considers likely future challenges in this research environment.

Full text not available from this repository.

More information

Published date: July 2007
Keywords: psychotropic drugs, evaluation, anxiety, depression, drug development, placebo, psychopharmacology, randomized controlled trials

Identifiers

Local EPrints ID: 62286
URI: https://eprints.soton.ac.uk/id/eprint/62286
PURE UUID: 901f3a5c-f43b-4c4d-adbf-c9d4e3a60501

Catalogue record

Date deposited: 12 Sep 2008
Last modified: 13 Mar 2019 20:27

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×